Determination of both the degree and duration of the immunity provided after receivingthe BNT162b2 vaccine against SARS-Cov-2.
The purpose of this study is to assess the kinetics of antibodies against SARS-CoV-2 as
well as the kinetics of the immune system's cell subpopulations and cytokines associated
with the immune system in healthy volunteers receiving the BNT162b2 vaccine against
SARS-Cov-2 of the Pfizer/BioNTech companies or any other vaccine authorized and
administered by the Ministry of Health. Immunoassays will be performed at serum
collection points before and after vaccination, as set out in this study.
Biological: BNT162b2
Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies
Biological: Other vaccine against SARS-Cov-2
Any other vaccine authorized and administered by the Greek Ministry of Health against
SARS-Cov-2
Inclusion Criteria:
- Healthy volunteers and all individuals who, according to the instructions of the
Greek State are considered eligible to receive the BNT162b2 vaccine
- Age ≥ 18 years old
Exclusion Criteria:
- Serious allergy problems i.e. hospitalization due to a serious allergic reaction
(anaphylaxis)
Department of Clinical Therapeutics, General Hospital of Athens ALEXANDRA
Athens, Greece
Investigator: Evangelos Terpos, MD
Ioanna Charitaki
+30 6976156403
j.charitaki@gmail.com
Evangelos Terpos, Principal Investigator
National and Kapodistrian University of Athens